Verastem, Inc.

Day range

$9.34 – $10.16

Open

$10.00

Prev close

$10.04

Volume

2.71M

Market cap

$909.26M

Shares out

90.56M

P/E

—

P/S

10.39

P/B

18.19

P/FCF

—

ROE

-405.5%

ROA

-98.2%

Debt/Equity

1.63

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsOct 14, 2026

  Among five evaluable patients with KRAS G12D-mutant advanced NSCLC ... all patients (5/5) achieved complete clearance of detectable KRAS G12D ctDNA.

• Underwriting agreementOct 14, 2026

  On October 14, 2026, Verastem, Inc. ... entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters ... The Underwriting Agreement contains customary representations, warranties, and agreements by the Company and customary conditions to closing, indemnification obligations ... and termination provisions.

• Credit facilityAug 7, 2026

  On August 6, 2026, Verastem, Inc. entered into Amendment No. 3 to that certain Note Purchase Agreement, dated as of January 13, 2025, as previously amended by Amendment No. 1 dated as of October 31, 2025 and Amendment No. 2 dated as of March 2, 2026. The Amendment amends the financing arrangement under the Note Purchase Agreement by establishing two separate series of senior secured notes: (i) 'Initial Notes,' which are the notes in an initial aggregate principal amount of $75.0 million previously issued on the Original Closing Date, and (ii) 'Revenue Notes,' which are a new series of notes to be issued in two tranches under the Note Purchase Agreement with an aggregate purchase price of up to $75.0 million.

• Investor presentationJun 23, 2026

  On June 23, 2026, Verastem, Inc. (the 'Company' or 'Verastem') posted a presentation to its website, which the Company intends to use during its previously announced investor conference call and webcast to review the preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375.

Days to cover

7.0

Short interest

14.96M

Avg volume

2.15M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight
  positiveGlobeNewswire Inc.· Oct 26, 2026
• Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?
  positiveZacks Investment Research· Oct 12, 2026
• Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?
  positiveZacks Investment Research· Oct 6, 2026
• Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
  positiveZacks Investment Research· Sep 8, 2026
• KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight
  positiveGlobeNewswire Inc.· Nov 12, 2025